Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Although several randomised trials in patients with triple-negative breast cancer have shown that the addition of carboplatin, with or without poly(ADP-ribose) polymerase (PARP) inhibitors, to neoadjuvant chemotherapy increases the likelihood of achieving a pathological complete response, the use of these therapies in this setting has remained controversial. The BrighTNess trial was designed to assess the addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol

Title: The Lancet. Oncology

Publisher: Elsevier BV

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): April 2018

Volume: 19

Issue: 4

Affiliations

[1 ] German Breast Group, Neu-Isenburg, Germany; Centre for Haematology and Oncology Bethanien, Frankfurt, Germany. Electronic address: sibylle.loibl@gbg.de.

[2 ] Baylor University Medical Center, Dallas, TX, USA.

[3 ] HELIOS Klinikum Berlin-Buch, Berlin, Germany.

[4 ] Women & Infants Hospital of Rhode Island, Providence, RI, USA.

[5 ] University of California San Francisco Hellen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.

[6 ] AbbVie Inc, North Chicago, IL, USA.

[7 ] Ulm University, Ulm, Germany.

[8 ] Brigham and Women's Hospital, Boston, MA, USA.

[9 ] German Breast Group, Neu-Isenburg, Germany.

[10 ] National Surgical Adjuvant Breast and Bowel Project Foundation, Pittsburgh, PA, USA.

[11 ] Texas Oncology, US Oncology, Dallas, TX, USA.

[12 ] Alicante University General Hospital, ISABIAL, GEICAM (Spanish Breast Cancer Research Group), Alicante, Spain.

[13 ] Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

[14 ] National Surgical Adjuvant Breast and Bowel Project Foundation, Pittsburgh, PA, USA; Magee-Womens Hospital, Pittsburgh, PA, USA.

[15 ] University of Texas MD Anderson Cancer Center, Houston, TX, USA.

[16 ] National Surgical Adjuvant Breast and Bowel Project Foundation, Pittsburgh, PA, USA; Virginia Commonwealth University Massey Cancer Center, Richmond, VA, USA.

Article

Publisher Item ID: S1470-2045(18)30111-6

DOI: 10.1016/S1470-2045(18)30111-6

PubMed ID: 29501363

SO-VID: 529aae23-10a6-48a5-84f1-5755245239e0

History

Data availability:

Comments

Comment on this article

scite_

Cited by 298

See all cited by

- Version 1